-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Prevention trials of anti-amyloid agents would ideally enroll those who first showed biologically relevant β-amyloid (Aβ) binding on positron emission tomography (PET)
This longitudinal multicenter cohort study included 3 independent cohorts: PREVENT-AD (data collected 2012-2020), ADNI (2005-2019), and HABS (2011-2019)
Results A total of 817 participants were included, including 129 from the PREVENT-AD cohort (mean [SD] age, 63.
Participants with extensive amyloid binding further exhibited significant cognitive decline (significant β = -0.
Taken together, regional Aβ binding appears to be biologically relevant, and participants at this stage remain relatively free of CSF phosphorylated tau181, tau-PET binding and associated cognitive decline, making them anti-amyloid agents ideal target
references:
Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition.